Weisel, K. Et Al. 2020. Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. LEUKEMIA & LYMPHOMA , vol.61, no.8 , 1850-1859.

Weisel, K., Dimopoulos, M., Moreau, P., Yagci, M., Larocca, A., Kanate, A. S., ... VURAL, F.(2020). Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. LEUKEMIA & LYMPHOMA , vol.61, no.8, 1850-1859.

Weisel, Katja Et Al. "Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma," LEUKEMIA & LYMPHOMA , vol.61, no.8, 1850-1859, 2020

Weisel, Katja Et Al. "Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma." LEUKEMIA & LYMPHOMA , vol.61, no.8, pp.1850-1859, 2020

Weisel, K. Et Al. (2020) . "Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma." LEUKEMIA & LYMPHOMA , vol.61, no.8, pp.1850-1859.

@article{article, author={Katja Weisel Et Al. }, title={Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma}, journal={LEUKEMIA & LYMPHOMA}, year=2020, pages={1850-1859} }